Evidence in favour
- 6 distinct acquisition events survive duplicate and security-type controls.
- Participation spans 8 named insiders rather than one filing source.
Company insider dossier
Verrica Pharmaceuticals Inc insider intelligence
VRCA filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.
83/100
Conviction accumulation
71/100 confidence- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Latest evidence
- 18 Aug 2026
Investment committee read
Conviction accumulation
Priced common-share acquisitions carry more weighted evidence than disposals after freshness, role, size, and duplicate controls.
Research constructive setupsDecision risks
- Reported purpose is unavailable in this feed, so even priced common-share transactions need filing context.
Price confirmation map
Weekly price with common-share events
Acquisitions and disposals are aligned to the nearest completed weekly bar.
Mar 2025Sep 2026
Weekly closeCommon-share acquisitionCommon-share disposal
Market confirmation
Price and trend context
- Latest close
- 5.30 USD
- One-week move
- -6.9%
- Four-week move
- +4.3%
- Fair-value gap
- -77.2%
- Trend signal
- Inactive
- Relative strength
- -19.1
Directional balance
Controlled event mix
100.0%acquisition
- Acquisition events
- 6
- Disposal events
- 0
- Net value
- $210.9K
Cadence
Twelve-week filing pressure
Volume shows attention. Controlled events determine direction.
015 Jun
022 Jun
029 Jun
006 Jul
013 Jul
020 Jul
027 Jul
003 Aug
110 Aug
517 Aug
024 Aug
031 Aug
Named participants
Insider conviction by person
RIEGER, JAYSONDirector, CEO and President752 events
ROSENBERG, NOAH L.CMO752 events
KIRBY, JOHN J.Interim CFO721 events
ZAWITZ, DAVIDChief Operating Officer721 events
CORCORAN, GAVINDirector500 events
EICHENFIELD, LAWRENCEDirector500 events
NGUYEN, DIEMDirector500 events
PRYGOCKI, MARK A SRDirector500 events
Evidence quality
Security and transaction context
Role architecture
Who is participating
Transaction evidence
Auditable VRCA filing ledger
Showing 1 to 13 of 13.
KIRBY, JOHN J.Interim CFO
AcquisitionCommon equity
5000 sharesCommon Stock
$24.6KDirectional evidence
ROSENBERG, NOAH L.CMO
AcquisitionCommon equity
2030 sharesCommon Stock
$10.0KDirectional evidence
ZAWITZ, DAVIDChief Operating Officer
AcquisitionCommon equity
6000 sharesCommon Stock
$29.9KDirectional evidence
RIEGER, JAYSONDirector, CEO and President
AcquisitionCommon equity
5000 sharesCommon Stock
$24.6KDirectional evidence
ROSENBERG, NOAH L.CMO
AcquisitionCommon equity
4200 sharesCommon Stock
$20.6KDirectional evidence
RIEGER, JAYSONDirector, CEO and President
AcquisitionCommon equity
20000 sharesCommon Stock
$101.2KDirectional evidence
CORCORAN, GAVINDirector
AcquisitionOptions and derivatives
16000 sharesStock Option (right to buy)
Not reportedContext evidence
EICHENFIELD, LAWRENCEDirector
AcquisitionOptions and derivatives
16000 sharesStock Option (right to buy)
Not reportedContext evidence
NGUYEN, DIEMDirector
AcquisitionOptions and derivatives
16000 sharesStock Option (right to buy)
Not reportedContext evidence
PRYGOCKI, MARK A SRDirector
AcquisitionOptions and derivatives
16000 sharesStock Option (right to buy)
Not reportedContext evidence
RIEGER, JAYSONDirector, CEO and President
AcquisitionOptions and derivatives
512269 sharesEmployee Stock Option (right to buy)
Not reportedContext evidence
ROSENBERG, NOAH L.CMO
AcquisitionOptions and derivatives
233840 sharesEmployee Stock Option (right to buy)
Not reportedContext evidence
ZAWITZ, DAVIDChief Operating Officer
AcquisitionOptions and derivatives
171340 sharesEmployee Stock Option (right to buy)
Not reportedContext evidence
Reading the dossier
Direction and confidence are separate
Conviction
The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.
Confidence
Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.
Disposals
Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.
Price confirmation
The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.
Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.